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Background: Performance of the histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 ELISA) and
malaria SYBR Green I fluorescence (MSF) drug sensitivity tests were directly compared using Plasmodium falciparum
reference strains and fresh ex vivo isolates from Cambodia against a panel of standard anti-malarials. The objective
was to determine which of these two common assays is more appropriate for studying drug susceptibility of
“immediate ex vivo” (IEV) isolates, analysed without culture adaption, in a region of relatively low malaria transmission.
Methods: Using the HRP-2 and MSF methods, the 50% inhibitory concentration (IC50) values against a panel of malaria
drugs were determined for P. falciparum reference clones (W2, D6, 3D7 and K1) and 41 IEV clinical isolates from an area
of multidrug resistance in Cambodia. Comparison of the IC50 values from the two methods was made using Wilcoxon
matched pair tests and Pearson’s correlation. The lower limit of parasitaemia detection for both methods was
determined for reference clones and IEV isolates. Since human white blood cell (WBC) DNA in clinical samples is
known to reduce MSF assay sensitivity, SYBR Green I fluorescence linearity of P. falciparum samples spiked with WBCs
was evaluated to assess the relative degree to which MSF sensitivity is reduced in clinical samples.
Results: IC50 values correlated well between the HRP-2 and MSF methods when testing either P. falciparum reference
clones or IEV isolates against 4-aminoquinolines (chloroquine, piperaquine and quinine) and the quinoline methanol
mefloquine (Pearson r = 0.85-0.99 for reference clones and 0.56-0.84 for IEV isolates), whereas a weaker IC50 value
correlation between methods was noted when testing artemisinins against reference clones and lack of correlation
when testing IEV isolates. The HRP-2 ELISA produced a higher overall success rate (90% for producing IC50 best-fit
sigmoidal curves), relative to only a 40% success rate for the MSF assay, when evaluating ex vivo Cambodian isolates.
Reduced sensitivity of the MSF assay is likely due to an interference of WBCs in clinical samples.
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Conclusions: For clinical samples not depleted of WBCs, HRP-2 ELISA is superior to the MSF assay at evaluating fresh
P. falciparum field isolates with low parasitaemia (<0.2%) generally observed in Southeast Asia.
Keywords: Immediate ex vivo Plasmodium falciparum drug susceptibility testing, HRP-2 ELISA, Malaria SYBR green
fluorescence assay, CambodiaBackground
In vitro testing of Plasmodium falciparum field isolates
for susceptibility against currently applied anti-malarials
provides an early warning of drug failure and possible
clinical resistance. Several methods are commonly used
to measure P. falciparum in vitro drug susceptibility, such
as the schizont maturation test [1], [3H]-hypoxanthine
incorporation [2], histidine-rich protein-2 enzyme linked
immunosorbent assay (HRP-2 ELISA) [3,4], and most re-
cently the malaria SYBR Green I fluorescence (MSF) assay
[5,6]. The schizont maturation assay is based on micro-
scopic examination for P. falciparum blood stage growth
during drug exposure. Although relatively inexpensive, this
assay is labour intensive and interpretation of results is
subjective. The [3H]-hypoxanthine uptake assay involves
measuring parasite growth by recording levels of hypo-
xanthine incorporated into parasite DNA [2]. While this
method provides accurate and reliable results, the major
drawback is the use of radioactivity, the safe disposal of
which demands substantial resources. The HRP-2 method
assesses parasite growth by using colorimetric ELISA to
measure P. falciparum HRP-2 protein. This method offers
a solution to examining drug susceptibilities of field isolates
using a non-radioactive procedure that is also more cost
effective compared to the [3H]-hypoxanthine method [3].
Recently, the MSF assay was developed based on measuring
the incorporation of the fluorescent SYBR Green I dye into
parasite DNA. This method relies on a single step of DNA
staining, which is less labour intensive compared to an
ELISA method, and is more amenable for high throughput
screening of new drug candidates [7]. However, utility of
the MSF assay in clinical isolates could be compromised
in samples with a relatively low parasitaemia, because of
non-specific fluorescence background attributed to SYBR
Green I binding to human DNA of white blood cells
(WBCs) that may reduce sensitivity of parasite detection [8].
Since 2004, Armed Forces Research Institute of Medical
Sciences (AFRIMS) routinely applies the HRP-2 ELISA for
“immediate ex vivo” (IEV) drug susceptibility testing of
fresh P. falciparum field isolates without culture adaptation
from multidrug resistant areas in Cambodia and Thailand
[9-12]. This method generates IC50 results comparable to
the World Health Organization (WHO) microplate schizont
maturation test and the [3H]-hypoxanthine uptake assay,
while offering the advantages of rapidity relative to the
schizont maturation test and avoiding radioisotope use [4].Moreover, measuring drug susceptibility of fresh para-
site isolates without culture adaptation provides results
that more accurately reflect the overall drug susceptibility
phenotype of an in vivo infection by avoiding loss of drug-
resistant parasite subpopulations during culture adapta-
tion [13-15]. The HRP-2 ELISA performs robustly when
analysing fresh isolates of relatively low parasitaemia. For
example, in a previous related field investigation of mal-
aria drug resistance, the HRP-2 assay had a success rate
of 75% for IC50 value determination in samples col-
lected during a survey in Cambodia and Thailand of
590 P. falciparum IEV isolates, of which nearly half
had <0.2% parasite density [9].
Recently, several papers evaluated the utility of the MSF
assay for measuring the drug susceptibility of P. falciparum
reference and field isolates from Africa, where malaria
transmission and thus patient parasitaemia are commonly
higher than in Southeast Asia. The MSF assay produces
comparable IC50 results to those generated by traditional
[3H]-hypoxanthine incorporation and HRP-2 ELISA meth-
ods [5,6,16,17], but presumably only when parasitaemia is
sufficiently high to produce reliable results. For example, a
study conducted in Madagascar reports that the MSF
method works well, with an overall 80% success rate of
generating IC50 results when testing fresh P. falciparum
samples of least 0.1% parasitaemia and washed three times
prior to plating [17]. Another report [16] using fresh iso-
lates from non-immune travellers who acquired malaria in
West Africa indicates that the MSF assay yields the same
success rate as the HRP-2 ELISA method when analysing
samples with a mean parasitaemia of 0.75%, also washed
three times prior to plating. In a recent investigation [6] of
IEV isolates collected from western Kenya, the MSF assay
produced a success rate of 78% with a parasitaemia >0.5%,
whereas the success rate decreased to only 61% in samples
with ≤0.5%.
However, the MSF assay is not expected to perform
well to evaluate field isolates in whole blood samples col-
lected from patients with lower parasitaemia. For example,
a comparison of the MSF and HRP-2 ELISA methods for
measuring in vitro susceptibilities of P. falciparum la-
boratory reference strains showed that the HRP-2 assay
provides a similar limit of detection in either whole
blood-media mixtures or WBC-free samples, whereas
sensitivity of the MSF assay diminishes greatly in samples
spiked with WBCs as a result of confounding fluorescence
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result of SYBR Green I binding to WBC DNA, is further
problematic in P. falciparum reference samples of lower
parasitaemia <1.0% [8], as is typically encountered in re-
gions of low malaria transmission. To date, a direct
comparison of MSF versus HRP-2 methods has not been
conducted using fresh clinical isolates of P. falciparum
with such low parasitaemia.
The study described herein was conducted to evaluate
utility of the HRP-2 ELISA versus MSF methods for deter-
mining ex vivo drug susceptibility of fresh P. falciparum
isolates from Cambodia, representing an area of relatively
low parasite transmission and thus low parasite density in
patients. The hypothesis was that the HRP-2 ELISA would
be more sensitive than the MSF assay when testing fresh
clinical isolates of low parasitaemia (<0.2%).
Methods
Plasmodium falciparum culture and synchronization
Plasmodium falciparum reference strains W2, D6, 3D7,
and K1 were maintained as described previously [18].
Briefly, cryopreserved vials of reference clones were
recovered using 3.5% sodium chloride [19] and maintained
in RPMI-1640 medium containing 25 mM HEPES, 25 mM
sodium bicarbonate, 5% human O+ erythrocytes, 10% pooled
AB+ serum and 0.1 mg/mL gentamycin at 37°C with 5%
CO2, 5% O2, and 90% N2. To obtain a predominance
(≥90%) of ring stage parasites for drug susceptibility test-
ing, 5% D-sorbitol synchronization was performed as pre-
viously described [20,21]. After synchronization, parasites
were maintained for 48 hours prior to conducting the
drug susceptibility assay.
Plasmodium falciparum isolate collection and
sample processing
Clinical P. falciparum isolates were obtained from patients
with uncomplicated falciparum malaria enrolled in an anti-
malarial drug resistance surveillance study in Cambodia.
The study was approved by the Cambodian National Ethics
Committee for Health Research (NECHR), and the Walter
Reed Army Institute of Research (WRAIR) Institutional
Review Board (protocol number: WRAIR 1576). After
signing informed consent, malaria patients ≥ 13 years
old without a history of anti-malarial drug use within
the previous seven days were enrolled into the study.
Diagnosis of malaria was conducted using Giemsa-stained
peripheral blood smears, with microscopy species deter-
mination verified using real-time PCR targeting the 18 s
rRNA as reported elsewhere [9]. A total of 41 isolates, col-
lected from volunteers with mono P. falciparum infection
living in northern (Preah vihear province) and southern
Cambodia (Kampong Spou, Kampot, and Preah Sihanouk
provinces) during May -October 2011, were evaluated in
the HRP-2 and MSF assays. At the time of diagnosis(before treatment), patient blood samples (4 ml of venous
blood in sodium heparin tubes) were tested for IEV drug
susceptibility, without a leukocyte depletion step or cul-
ture adaptation, as previously described [9]. Samples were
applied to dried drug plates for HRP-2 and MSF assay
analysis within six hours after phlebotomy.Preparation of dried drug plates
Dried drug plates, for use in the HRP-2 and MSF assays,
were prepared using published methods [9]. Briefly, six
drugs, dihydroartemisinin (DHA), artesunate (AS), meflo-
quine hydrochloride (MQ), quinine sulphate hydrate (QN),
chloroquine diphosphate (CQ), and anhydrous piperaquine
phosphate (PPQ), were coated onto 96-well plates in dupli-
cate. Molecular weights of DHA, AS, MQ, QN, CQ, and
PPQ used were 284.35, 384.42, 414.78, 782.97, 515.92,
and 927.57 g/mol, respectively. All test drugs were pro-
vided by the WRAIR (Silver Spring, MD, USA). Drugs were
dissolved in 70% ethanol to make 1 mg/ml stock solutions,
with the exception of using 0.5% lactic acid in distilled
water as a solvent for PPQ. The drug stock solutions
were then diluted to appropriate concentrations in ster-
ile distilled water. Three-fold serial drug dilutions were
performed on plates to reach final concentrations (after
200 μL of sample added) ranging from: 0.027 to 20 ng/ml
for DHA and AS, 0.274 to 200 ng/ml for MQ, 1.71 to
1,250 ng/mL for QN, 2.74 to 2,000 ng/ml for CQ, and
0.86 to 625 ng/mL for PPQ. The top row of each plate
served as a drug-free control for parasite growth. Drug
plates were dried overnight in a running biosafety cabinet
and stored at 4°C up to eight weeks prior to use. As a
quality control for dried drug plate integrity during trans-
port to and from field sites, a subset of plates not used in
the assays were tested to ensure an acceptable range of
IC50 values was attained against the P. falciparum W2 ref-
erence clone, as described previously [21].HRP-2 ELISA and MSF Plasmodium falciparum
susceptibility testing
Performance of HRP-2 ELISA and MSF methods was
evaluated side-by-side in P. falciparum reference lines
and in Cambodian IEV isolates. Each reference clone or
fresh isolate sample was added to the same drug-coated
plates, which were later processed for each assay as de-
scribed below. Synchronized cultures of P. falciparum
reference strains with ≥90% ring forms were diluted to
0.5% parasitaemia with 1.5% haematocrit in 0.5% Albumax
RPMI 1640, and transferred to dried drug-coated plates.
Plates were incubated at 37°C with 5% CO2, 5% O2, and
90% N2 for 72 hours. For IEV drug susceptibility testing,
blood samples with ≤0.5% parasitaemia were transferred
to dried drug-coated plates without sample dilution and
those with >0.5% parasitaemia were diluted to 0.2-0.5%
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bated at 37°C using a candle jar, instead of mixed gas.
After 72 hours of incubation, plates were frozen and
thawed and then analysed in parallel for parasite growth
inhibition by HRP-2 and MSF assay. For HRP-2 assay
analysis, culture samples were diluted before performing
ELISA as described in Rutvisuttinunt et al. [21] and Tyner
et al. [9]. The MSF assay was performed according to
Johnson et al. [5]. Briefly, for the MSF assay 100 μL of
samples per well were transferred to Optiplate-96 F black
plates (Perkin Elmer, Salem, MA, USA) prior to adding
100 μL lysis buffer [20 mM Tris (pH 7.5), 5 mM EDTA,
0.008% (wt/vol) saponin, and 0.08% (vol/vol) Triton X-100]
containing SYBR Green I (1X final concentration). Plates
were incubated for one hour in the dark at room tem-
perature and then relative fluorescence unit (RFU) mea-
surements in each well were made using a Victor plate
reader (Perkin Elmer, Salem, MA, USA) at an excitation/
emission wavelength of 485/535 nm. HRP-2 optical dens-
ities (OD) and SYBR Green RFU of duplicate wells were
averaged and plotted against drug concentrations. IC50
values were estimated by nonlinear regression analysis
using the ICEstimator program [22].
Assessing SYBR Green fluorescence linearity and
detection limit for parasitaemia
SYBR Green fluorescence linearity of parasitaemia be-
tween 0-10% was examined by serially diluting synchro-
nized P. falciparum ring forms of strains 3D7 and K1
with non-infected erythrocytes as described previously
[5]. Briefly, two-fold serial dilutions of parasite cultures
were performed using non-infected erythrocytes with
1.5% haematocrit in culture medium. Then 100 μL cell
media mixture with varying levels of parasitaemia and
non-infected erythrocyte samples were added in 12 repli-
cate wells in each row of the 96-well plates. Next, 100 μL
lysis buffer containing SYBR Green I dye (1X final concen-
tration) was added before incubating plates for one hour
in the dark at room temperature, followed by taking RFU
measurements as previously described. To assess fluor-
escence linearity in P. falciparum samples spiked with
WBCs, similar procedures were done, but using only
50 μL of samples with varying parasite densities and non-
infected erythrocyte samples in 12 replicate wells of each
row. Next 50 μL of 1.5% haematocrit blood containing
17,000 WBC/μL was added to yield samples with 0-5%
parasitaemia containing 8,500 WBC/μL, representing
maximum WBC counts observed in malaria patients in
Cambodia [10]. After subtraction of non-infected erythro-
cyte background, average RFUs of 12 replicate wells were
plotted on the Y axis against % parasitaemia on the X axis.
Linear regression line, r2, limit of detection (LOD), and
limit of quantitation (LOQ) were determined using MS
Excel. Up to three experiments were conducted to yieldthe LOD and LOQ range, calculated as per International
Conference on Harmonization (ICH) guidelines using the
equations below.
LOD ¼ 3  the residual standard deviation
=slope of a regression line
LOQ ¼ 10  LOD=3
Reliability of HRP-2 and MSF drug susceptibility assays in
samples with low parasitaemia and effect of % parasitaemia
on IC50 values
To examine performance of HRP-2 ELISA and MSF drug
susceptibility methods in samples with low parasitaemia,
P. falciparum W2 and D6 parasites were applied to dried
drug plates at varying parasitaemia of 0.005, 0.01, 0.05,
0.2, and 0.5% and the assays were conducted as described
above. Two experiments were performed for each refer-
ence strain. The lowest tested parasitaemia that produced
best-fit sigmoidal concentration-response curves resulting
in IC50 values was determined for each method. In addition,
IC50 values obtained from varying parasitaemia were com-
pared to investigate the effect of baseline parasitaemia (in-
oculum effect) on IC50 values.
For IEV drug susceptibility testing, reliability of the
HRP-2 and MSF methods in samples with low parasitaemia
was evaluated as the assay success rate when testing DHA,
AS, MQ, QN, CQ, and PPQ activities. A “successful” IC50
assay result for each P. falciparum clinical isolate was
defined as achieving a sigmoidal concentration-response
with an IC50 confidence interval ratio ≤ 5 when testing six
serial drug dilutions for at least one of the tested drugs.
Statistical analysis
IC50 values obtained from HRP-2 ELISA and MSF methods
were compared using Wilcoxon matched pair tests. Log
transformed IC50 values were utilized to analyse the cor-
relation and agreement between the two methods using
Pearson’s correlation and Bland-Altman plots, respectively
[4,23]. The Kruskal-Wallis test was performed to examine
the effect of baseline parasitaemia on HRP-2 ELISA IC50
values. Statistical analysis was performed using GraphPad
Prism (GraphPad Software, Inc, San Diego, CA, USA).
Results
SYBR green fluorescence linearity
The linearity of SYBR Green fluorescence in P. falciparum
reference strain samples was compared with and without
the addition of WBCs (Figure 1). For samples without
WBCs, a range of MSF assay LOD and LOQ values of
0.13-0.15% and 0.43-0.50% parasitaemia, respectively,
was determined from the results of three independent
experiments using either P. falciparum 3D7 or K1 refer-




























sample with WBCLOD - LOQ
y = 25195x + 6851
R2 = 0.95
y = 23125x + 673.9
R2 = 0.99
LOD - LOQ
Figure 1 SYBR Green I fluorescence linearity in Plasmodium
falciparum ring stages of 0-10% parasitaemia. Data points show
average RFUs of 12 replicate wells, derived from one experiment
using the P. falciparum K1 clone, plotted on the Y axis against %
parasitaemia on the X axis. Red and black symbols, lines, and letters
represent samples spiked with 8,500 WBC/μL and samples without
WBCs, respectively. Regression line and R2 are shown. Dashed lines
indicate LOD and LOQ range parasitaemia values obtained from up
to three experiments.
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by higher LOD and LOQ values of 0.62/0.72% and 2.06/
2.41% parasitaemia, respectively, from two independent
experiments.
HRP-2 and MSF assay comparisons
In vitro drug susceptibility testing
The HRP-2 and MSF assays were evaluated simultaneously
using a 0.5% baseline parasitaemia of in vitro P. falciparum
reference strains with varying drug susceptibility profiles:
W2 and K1 (susceptible to mefloquine, and resistant to
chloroquine), D6 (susceptible to chloroquine, and resistant
to mefloquine), and 3D7 (susceptible to chloroquine, but
less susceptible to mefloquine than W2). From the IC50
profiles of all parasite laboratory strains (Figure 2A), both
HRP-2 and MSF assays consistently differentiated sen-
sitive from resistant strains against MQ, QN and CQ.
Although overall IC50 values obtained from the HRP-2
ELISA were slightly higher than those from the MSF
method (Figure 2A), significant correlations between both
methods were found in all drugs tested (r = 0.73-0.99), ex-
cept for DHA (Figure 3A). Analysis of pooled IC50s of all
drugs tested revealed that both methods were significantly
correlated (r = 0.97, p < 0.0001, Figure 3A). A Bland-Altman
plot of IC50 values for all drugs is shown in Figure 4A, indi-
cating a bias of −0.07 log units and limit of agreement be-
tween the two methods from −0.36 to 0.23 in log scale,
further suggesting that results produced from both assays
are comparable when testing in vitro reference strains.
Immediate ex vivo drug susceptibility testing
A total of 41 fresh P. falciparum isolates were analysed
for IEV drug susceptibility using the HRP-2 and MSFassays in parallel. Success rate, defined as the propor-
tion of samples in which it is possible to determine an IC50
value from a sigmoidal curve, appears to be dependent on
baseline parasitaemia, as shown in Table 1. The HRP-2
ELISA demonstrated a high success rate (90%), whereas the
MSF method was successful at determining IC50s in only
40% of samples. Of the total isolates tested, IC50 values
were determined for 15 isolates using both assays. These 15
paired IC50 comparisons demonstrated consistently lower
IC50s obtained from the HRP-2 ELISA than those from the
MSF method for MQ, QN, and CQ (Figure 2B). Significant
correlations between IC50s obtained from the two methods
were found in all drugs tested, r = 0.56-0.84, except for
DHA and AS, and good correlation was found for pooled
IC50s against all drugs (r= 0.94, P < 0.0001, Figure 3B). A
Bland-Altman plot of IC50s for all drugs tested is shown in
Figure 4B, indicating a bias of 0.12 and limit of agreement
between two methods from −0.41 to 0.64 in log scale, indi-
cating tight correlation between the two methods when
evaluating field isolates.
Reliability of HRP-2 and MSF assays in samples with
low parasitaemia
Two independent experiments were performed using W2
and D6 parasites to determine the lowest parasitaemia
capable of producing sigmoidal concentration-response
curves to determine IC50 values using the HRP-2 and
MSF assays. Samples with a parasitaemia of 0.005, 0.01,
0.05, 0.2, and 0.5% were tested for in vitro drug susceptibil-
ity. For HRP-2 ELISA, a valid IC50 value was determined
with minimal baseline parasitaemia as low as 0.005% or
0.05%, depending on the rate of parasite growth during
72 hours’ incubation. In contrast, the MSF assay requires
an approximately one order of magnitude higher baseline
parasitaemia range of 0.01-0.2%, relative to direct com-
parison using HRP-2 ELISA in the same samples, to pro-
duce IC50 values.
Similarly, when evaluating IEV isolates, the MSF overall
success rate (37%) was lower than for HRP-2 ELISA (90%).
The MSF assay required ≥0.2% baseline parasitaemia for
success, whereas the HRP-2 assay can produced results
from isolates with parasitaemia <0.2% (Table 1).
Effect of % parasitaemia on IC50 values
The effect of low baseline parasitaemia applied to the
HRP-2 assay was evaluated because lower parasitaemia
samples could produce an ‘inoculum effect’, a potential
source for drug sensitivity test result variability resulting
in lower IC50 values produced with lower baseline parasite
density [24]. Low baseline parasitaemia for P. falciparum
W2 and D6 reference strains of 0.005, 0.01, 0.05, 0.2, and
0.5% were tested in the HRP-2 assay in 2 independent
experiments. This range of parasitaemia was chosen be-




































W2 : N = 14
D6  : N = 14
3D7: N = 8
K1  : N = 6
3.41    2.13
3.90    3.09
6.00    2.97
4.06    2.09
4.23    3.49
6.02    5.93
10.15  4.54
3.52    3.38
25.22   21.58
73.51   53.63
66.32   42.7
16.25   8.99
203.62   165.49
32.95     30.51
32.23     31.26
199.65   177.3
324.30   249.55
17.21    19.40
21.91    16.79
603.36  426.00
21.98    21.04
11.41    12.29
21.00    18.50






 = -11.07 NS
P = 0.002* P = 0.011*
 = -43.71  = -43.71
A. P. falciparum reference clone results





































Figure 2 Direct comparison of IC50 values obtained using the HRP-2 and MSF assays. (A) IC50s of reference laboratory clones (WBCs absent).
Median IC50 values for each drug against W2, D6, 3D7 and K1 strains are indicated using different symbols/colours (n = number of IC50 values attained
for each strain from 3–5 experiments). (B) IEV IC50s of field isolates (WBCs present). Of the total 41 IEV isolates evaluated in both the HRP-2 and MSF
assays, IC50 values were obtained for both assays in 15 isolates. Median IC50 values for field isolates obtained by HRP-2 and MSF assays are shown as
black circles and red squares, respectively. Significant p-values of Wilcoxon matched pair tests comparing IC50s from HRP-2 and MSF assays and their
mean differences are designated with * symbol. NS signifies no statistical significance.
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attained for all parasite densities tested for W2, whereas
a parasitaemia <0.05% did not yield IC50 results for D6
(Figure 5). The results suggest that for all drugs tested
an inoculum effect was observed to a certain extent,
yielding higher IC50 values with increasing parasitaemia.
For instance, an inoculum effect was observed as statis-
tically significant lower IC50 values for DHA and AS when
evaluating samples with a low starting parasitaemia (<0.2%)
of P. falciparum W2 and D6 lines compared to higher
parasitaemia samples (Figure 5A, 5B). For PPQ, signifi-
cantly lower IC50 values were attained for a W2 baselineparasitaemia <0.05% (Figure 5D). For CQ, an inoculum
effect appears more obvious in the CQ-resistant W2 line
relative to the CQ-sensitive D6 strain (Figure 5F). Like-
wise, a more noticeable inoculum effect is noted for MQ
in the MQ-resistant D6 strain than in the MQ-susceptible
W2 clone (Figure 5C).
Discussion
This is the first study to report the direct comparison of
two field applicable methods, the HRP-2 and MSF as-
says, for evaluating drug resistance trends in immediate
ex vivo isolates from Southeast Asia. Although several
A. P. falciparum reference clone results
B. P. falciparum immediate ex vivo isolate results












DHA    :  r =  0.37,     p = 0.015
AS       :  r =  0.73,    p < 0.001*
MQ      : r  =  0.85,   p <  0.001*
QN      : r  =   0.96,  p < 0.001*
CQ      : r  =   0.99, p < 0.001* 
PPQ    : r  =   0.88, p < 0.001*
r = 0.97
p < 0.0001*











3 DHA   :r  =  0.34,  p  =   0.208
AS      :r  =  0.07,  p  =   0.788
MQ     :r  =  0.56,  p  =  0.058*
QN     :r  =  0.70,  p  =   0.012*
CQ     :r  =  0.67,  p  =   0.023*
PPQ   :r  =  0.84,  p  =   0.005*
r = 0.94
p < 0.0001*
Figure 3 Correlations between HRP-2 and MSF assay log [IC50], nM, results for reference strains and field isolates. (A) IC50s of reference
laboratory clones (WBCs absent). (B) IEV IC50s of 15 field isolates (WBCs present). Scatter plots are shown for the correlation of log [IC50s] of all
drugs tested by HRP-2 and MSF assays. P value and r from Pearson correlation are shown for all drugs together and each drug tested individually.
Significant correlations are designated with * symbol.
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evaluating P. falciparum isolates, all of these investiga-
tions used relatively high parasitaemia samples with
mostly ≥0.2% parasitaemia from Africa [6,17,25]. How-
ever, results reported here using 41 fresh P. falciparum
field isolates from Cambodia suggest that the HRP-2
ELISA offers superior sensitivity, compared to the MSF
assay, in lower parasitaemia samples (<0.2%) typical of
malaria infections endemic to Southeast Asia. For in-
stance, nearly half (49%) of clinical isolates collected from
prior drug resistance surveillance work in Cambodia
in 2009–2012 were <0.2% parasitaemia (AFRIMS data,
n = 209 isolates). In contrast, only 22% of field isolates
collected from Kenya in 2008–2009 were <0.2% para-
sitaemia (data from Kenya Medical Research Institute-
Walter Reed Project, Kisumu, n = 292 isolates). This
discrepancy in the success of the two methods in clinical
isolates appears to result from reduced sensitivity of the
MSF assay in lower parasitaemia samples containing
WBCs (Figure 1).
Good correlation of IC50 values for MQ, QN, CQ, and
PPQ was observed when comparing HRP-2 and MSF assay
results, but it is unclear why poor correlation betweenmethods was determined for the artemisinins (Figure 3).
One possibility relates to assay reliability linked to mode
and timing of drug action, since consistency of results for
anti-malarial drug susceptibility assays depends on these
drug-dependent variables [26]. Differences in methods for
measuring parasite growth could possibly result in varying
IC50 results. For instance, SYBR Green I fluorescence
measures DNA replication and thus is less likely to pro-
duce results biased on parasite growth stage [27], whereas
the HRP-2 protein is relatively stable and is actively se-
creted during parasite maturation stages [28]. However,
lack of a true artemisinin-resistant reference strain hinders
a meaningful comparison of methods. Unlike artemisinins,
P. falciparum reference clones and field isolates are
available that are resistant or sensitive to MQ, CQ and
QN, allowing for robust comparisons of drug susceptibil-
ity assays [21]. In the absence of a standard artemisinin-
resistant strain, further evaluation with more field isolates
is needed to understand the sensitivities of the HRP-2 and
MSF methods for differentiating artemisinin susceptibility
from resistance. However, it is highly likely that in vitro
assays will not detect resistance to fast-acting drugs,
such as the artemisinins, and delayed parasite clearance
A. P. falciparum reference clone results
B. P. falciparum immediate ex vivo isolate results
Average log IC 
50

































Mean  + 1.96 SD : 0.23
Mean  -  1.96  SD  : - 0.36
Mean : - 0.07
Average log IC 50 from HRP-2 ELISA and MSF assays






Mean  +  1.96  SD  : 0.64
Mean  -  1.96  SD : -0.41
Mean  :  0.12
Figure 4 Bland-Altman plots of the difference in log IC50s comparing HRP-2 and MSF assays. (A) Bland-Altman analysis results for
reference laboratory clones (WBCs absent). (B) Results for 15 IEV isolates (WBCs present) in which IC50 values were obtained for both assays.
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means for detecting artemisinin resistance [29,30].
Besides considering mechanism of drug action, the
effect of baseline parasitaemia is another variable to
consider when interpreting drug sensitivity assay resultsTable 1 Success rates for HRP-2 and MSF assays in fresh
Plasmodium falciparum isolates of varying parasitaemia
% parasitaemia Success case (% success rate) Total
casesHRP-2 ELISA MSF assay
<0.02% 1 (50%) 0 (0%) 2
0.02 - <0.2% 13 (87%) 0 (0%) 15
≥0.2% 23 (96%) 15 (63%) 24
Overall success 37 (90%) 15 (37%) 41
A total of 41 IEV Plasmodium falciparum isolates from Cambodia were
evaluated in both the HRP-2 and MSF assays to determine % assay
success rate.from clinical isolates. In the HRP-2 assay, a significant re-
duction in DHA and AS IC50 values was observed when
testing samples with a low starting parasitaemia (<0.2%) of
P. falciparum W2 and D6 lines relative to higher parasite
densities (Figure 5). This finding has been noted previ-
ously in a study reporting higher artemisinin IC50 values,
and thus an overestimation of artemisinin resistance, asso-
ciated with an inoculum effect in Gambian field isolates
[24]. Interestingly, for CQ, an inoculum effect was only
noted in the CQ-sensitive D6 line, whereas baseline para-
sitaemia did not appear to alter HRP-2 assay results in
the CQ-resistant W2 strain (Figure 5). A difference in
the chloroquine cellular accumulation ratio between
chloroquine-resistant and chloroquine-sensitive strains
could explain these findings. In particular, kinetic studies
suggest a faster rate of chloroquine accumulation in
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D.
Figure 5 Effect of baseline parasitaemia on IC50 values for drugs tested by HRP-2 ELISA. (A) DHA, (B) AS, (C) MQ, (D) PPQ, (E) QN, and
(F) CQ. Results presented are IC50 values for drugs against W2 and D6 strains obtained from 2 independent experiments. The Kruskal–Wallis test
was utilized to compare IC50 values when testing a range of parasitaemias from 0.005 to 0.5% for W2 parasites and from 0.05 to 0.5% for D6
parasites. Red stars indicate significant p-values and reduced IC50 values compared to those attained from a 0.5% parasitaemia baseline (p < 0.05
by Dunn’s Multiple comparison). Black circles and blue squares indicate IC50 values against W2 and D6, respectively. The dashed line in each
graph indicates low baseline parasitaemia (<0.2%).
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which could result in greater concentrations of drug (i.e.,
higher IC50 values) required to kill chloroquine-sensitive
strains with increases in inoculum size [32,33]. Overall,
these results suggest that lower baseline parasitaemias re-
duce HRP-2 IC50 values when evaluating highly suscep-
tible, rather than drug-resistant, parasites.
Thus, it is possible that IC50 values could be lower for
the artemisinins against susceptible clinical isolates of
lower parasitaemias (<0.2%). Indeed, in comparing HRP-2
assay IC50 results attained with parasitaemia <0.2% versus
≥0.2% in a total of 350 IEV isolates from Cambodia col-
lected in 2009–2012, significantly higher DHA and ASIC50 values were observed in samples with ≥0.2% para-
sitaemia (median IC50 of 8.2 for DHA and 6.5 for AS)
compared to those attained from isolates with <0.2%
parasitaemia (median IC50 of 6.2 for DHA and 4.1 for
AS). However, interpretation of these results is compli-
cated since isolates represent a mix of parasite popula-
tions, with potentially varying degrees of artemisinin
susceptibility. To avoid potential confounding results,
consistency in assay baseline parasitaemia was maintained
to appropriately evaluate drug resistance surveillance re-
sults in field isolates [9].
The main conclusion of the present study is that HRP-2
ELISA is a more effective field-ready method, compared
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http://www.malariajournal.com/content/12/1/239to the MSF assay, for analysing fresh clinical isolates of
relatively low parasitaemia. However, as reported in this
investigation and in previous reports [8,34], WBC deple-
tion to decrease non-specific SYBR Green fluorescence I
is expected to improve MSF assay sensitivity. Moreover,
elimination of haemoglobin that also interferes with fluor-
escence readings was found to increase signal and assay
sensitivity for low parasitaemia samples [34]. However,
such additional sample processing steps to improve MSF
assay performance in low parasitaemia isolates may ultim-
ately be time consuming and labour intensive to justify
practical use in the field. Since conducting this study, a
modified version of the MSF assay [35] was developed in-
volving a higher concentration of SYBR Green I dye and
other modifications that could improve performance of
the assay in field samples. Future efforts will investigate
the effect of improving MSF assay performance with
leucocyte depleted clinical isolates from Cambodia.Conclusions
In the context of clinical samples not processed for WBC
depletion, HRP-2 ELISA is superior to the MSF assay at
evaluating fresh P. falciparum isolates with low parasit-
aemia (<0.2%) typical of malaria endemic to Southeast Asia.
Follow-on efforts are aimed at determining if performance
of the MSF assay can be improved in fresh clinical isolates
of low parasitaemia by removing WBCs to reduce non-
specific SYBR Green I fluorescence. Ultimately, field de-
ployable malaria drug sensitivity assays must be convenient,
requiring minimal sample preparation and relatively simple
methods, and produce reliable results suitable for monitor-
ing drug resistance specific to the malaria-endemic region
of interest.Endnote
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